Osaic Holdings
TRDA icon

Osaic Holdings’s Entrada Therapeutics TRDA Stock Holding History

Osaic Holdings’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.44K Buy
195
+190
+3,800% +$1.82K ﹤0.01% 7377
2026
Q1 		$63 Sell
5
-190
-97% -$2.18K ﹤0.01% 7666
2025
Q4 		$2K Sell
195
-2
-1% -$17 ﹤0.01% 7096
2025
Q3 		$1.15K Sell
197
-14
-7% -$82 ﹤0.01% 7302
2025
Q2 		$1.42K Buy
+211
New +$1.7K ﹤0.01% 7055
2025
Q1 		– Sell
-407
Closed -$7.04K – 7707
2024
Q4 		$7.04K Buy
407
+30
+8% +$544 ﹤0.01% 6000
2024
Q3 		$6.02K Sell
377
-21
-5% -$331 ﹤0.01% 6112
2024
Q2 		$5.67K Buy
+398
New +$5.66K ﹤0.01% 6108
2023
Q4 		– Sell
-300
Closed -$4.74K – 7460
2023
Q3 		$4.74K Hold
300
– – ﹤0.01% 6296
2023
Q2 		$4.54K Hold
300
– – ﹤0.01% 6357
2023
Q1 		$4.35K Hold
300
– – ﹤0.01% 6395
2022
Q4 		$4K Hold
300
– – ﹤0.01% 6431
2022
Q3 		$5K Hold
300
– – ﹤0.01% 6395
2022
Q2 		$4K Buy
+300
New +$2.27K ﹤0.01% 6633
2022
Q1 		– Sell
-300
Closed -$5K – 7503
2021
Q4 		$5K Buy
+300
New +$7.28K ﹤0.01% 6661

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Osaic Holdings's TRDA Position: Q2 2026 in Review

Osaic Holdings increased its Entrada Therapeutics (TRDA) stake by 3,800% in Q2 2026, buying an estimated $1.82K and bringing the position to 195 shares worth $1.44K. The position accounts for ﹤0.01% of the portfolio, ranked #7377.

Osaic Holdings first reported a position in TRDA in Q4 2021 and has held it in 15 quarters since. The position peaked at $7.04K in Q4 2024. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Osaic Holdings held 195 shares of Entrada Therapeutics worth $1.44K as of Q2 2026.
  • Osaic Holdings bought 190 Entrada Therapeutics shares in Q2 2026, an estimated $1.82K.
  • Entrada Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #7377 holding.
  • Osaic Holdings first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Osaic Holdings's Entrada Therapeutics position peaked at $7.04K in Q4 2024.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.